Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting

Background and aims: Point-of-care tests (POCT) allow instant measurement of inflammatory markers and drug concentrations. Here, we studied agreement between a novel POCT device and reference methods of measuring infliximab (IFX) and adalimumab (ADL) serum concentrations and C-reactive protein (CRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Volkers, Adriaan, Löwenberg, Mark, Braad, Marlou, Abeling, Yara, Gecse, Krisztina, Berkers, Nicole, Montazeri, Nahid, D’Haens, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217227/
https://www.ncbi.nlm.nih.gov/pubmed/37238198
http://dx.doi.org/10.3390/diagnostics13101712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217227/
https://www.ncbi.nlm.nih.gov/pubmed/37238198
http://dx.doi.org/10.3390/diagnostics13101712

Ejemplares similares